Center-Authored Papers

Filters: Author is Schuster, Michael W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
336
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Acute Disease
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Adult
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Aged
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Aged, 80 and over
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Antineoplastic Agents
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Boronic Acids
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Clinical Research Division
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Clinical Trials as Topic
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Dexamethasone
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Drug Administration Schedule
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Endpoint Determination
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Epidemiologic Methods
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Female
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Graft vs Host Disease
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Humans
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P et al..  2009.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):777-84. Abstract
Male
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Middle Aged
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Multiple Myeloma
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Pyrazines
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Quality of Life
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
RECURRENCE
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract